沙美特罗替卡松粉剂吸入治疗支气管哮喘的临床评价(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 观察沙美特罗替卡松粉剂吸入后对支气管哮喘的治疗效果、安全性。 方法 将确诊的75例支气管哮喘患者随机分为试验组和对照组，试验组38例，给予沙美特罗替卡松粉吸入剂，每次1吸，每天2次；对照组37例，全身应用茶碱类、激动剂、祛痰药。两组常规给予宣教、戒烟、预防呼吸道感染及氧疗，疗程均为12周。治疗前后观察临床症状、肺功能[FEV1、FEV1/FVC(%)]。 结果 治疗后试验组临床症状、肺功能较治疗前均明显改善(P < 0.05)，并且试验组肺功能改善优于对照组，差异有统计学意义(P < 0.05)。 结论 沙美特罗替卡松粉吸入剂治疗支气管哮喘疗效肯定，安全性高，在基层医院的临床应用中效果显著。
[关键词] 沙美特罗替卡松；吸入剂；支气管哮喘；临床评价
[中图分类号] R562.2+5 [文献标识码] A [文章编号] 1674-4721(2012)02(b)-0078-02
Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone inhaler for the treatment of bronchial asthma
CHEN Junping
Medicine Department, Traditional Chinese Medicine Hospital of Xinfeng County in Guangdong Province, Xinfeng 511100, China
[Abstract] Objective To evaluate the clinical efficacy and the safety of salmeterol/fluticasone powder inhalers in controlling bronchial asthma. Methods Seventy five patients diagnosed with bronchus asthma were randomly divided into trial group and control group. During 12-week treatment, 38 patients in the trial group were prescribed salmeterol/fluticasone one actuation twice a day through inhaler, while 37 cases in the control group were received treatments such as theophylline, agonists and expectorants. Both groups were given patient education such as smoke abatement and respiratory infections prevention as well as oxygen therapy. Clinical symptoms and pulmonary function [FEV1 and FEV1/FVC (%)] were observed before and after treatment. Results After treatment, the clinical symptoms and lung function were markedly improved in the trial group (P < 0.05), with statistically significant better results than control group (P < 0.05). Conclusion In the clinical application at basic-level hospitals, salmeterol/fluticasone powder inhalers are effective and safe treatment for bronchial asthma with remarkable effect.
[Key words] Salmeterol/fluticasone; Inhaler; Bronchial asthma; Clinical evaluation
支气管哮喘是一种多种因素引起的呼吸道疾病，是常见的呼吸道疾病，发病率很高，如果急性发作，会严重影响患者的工作能力和生活质量。当前，尚没有完全根治哮喘的办法，但可以通过积极的治疗，有效预防和控制临床症状，减少急性发作的频率和严重程度，提高运动耐量。β受体激动剂和糖皮质激素类药物是临床治疗支气管哮喘的主要药物，其复合制剂具有扩张支气管、抗感染、平喘、止咳作用 ......
您现在查看是摘要介绍页，详见PDF附件(2582kb)。